WDB Medical Data (WDBMD) — a global provider of contract research organisation and R&D services to the biopharma and medical device industry — has acquired DZS Clinical Services, which provides clinical development and data analytic services.
Acquisition
Through the acquisition, WDBMD will allow DZS Clinical Services to strengthen its full-service CRO capabilities and provide more comprehensive and global services to US companies with coverage in Europe and Japan. Services include clinical development and operations support, data management, statistical services, medical writing pharmacovigilance and regulatory affairs in addition to access to a medical call centre.
“This acquisition and the addition of Greg Ambra and the DZS operations team complement our company and further our goal to provide even greater flexibility and affordability to more businesses and institutions worldwide,” said Norifumi Ninokata, president and CEO of WDBMD.
“Access to WDBMD’s expertise and global resources will increase our capacity and allow us to offer a broader range of services to our clients,” commented Greg Ambra, president of DZS Clinical Services.
The DZS Clinical Services leadership team will remain in place. In addition to its facilities in Bound Brook, New Jersey, DZS Clinical is establishing an office in Sunnyvale, California, to foster closer relationships with its West Coast-based clients. WDBMD, headquartered in Princeton, New Jersey, also operates its CRO business out of offices in Japan, India and Finland.